Triterpenoid Exposure and HO-1 Blockade Sensitize Neoplastic Mast Cells Against Midostaurin and Avapritinib
Cells · 2026
DOI: 10.3390/cells15201898 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2026. Verfasst von Max Vincent John und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria. Hauptthemen laut MEDLINE: Avapritinib, Mast Cells, Staurosporine, Heme Oxygenase-1. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Scientific Fund of the Mayor of the City of Vienna, Austrian Science Fund (FWF).
Abstract (Originalsprache)
Advanced systemic mastocytosis (advSM), including aggressive SM (ASM), SM with an associated hematologic neoplasm (SM-AHN) and mast cell leukemia (MCL), are rare, mostly KIT D816V-driven malignancies with a poor prognosis. KIT D816V-targeting drugs, such as midostaurin or avapritinib, can induce hematologic responses in most patients with advSM. However, relapses may occur. Therefore, current research focuses on novel drugs and drug combinations to improve outcomes in advSM. We here describe that the synthetic triterpenoids bardoxolone methyl and omaveloxolone suppress proliferation in various human MCL-like cell lines expressing or lacking KIT D816V, with IC50 values of 0.2–0.4 µM. Growth-inhibitory effects were accompanied by induction of apoptosis, decreased surface expression of CD44, CD71 and KIT, and downregulation of cytoplasmic AKT. Antiproliferative effects of bardoxolone methyl and omaveloxolone were also observed in primary neoplastic cells obtained from patients with advSM. Moreover, both synthetic triterpenoids were found to cooperate with midostaurin and avapritinib in suppressing the proliferation of HMC-1 and MCPV-1 cells. However, bardoxolone methyl and omaveloxolone also augmented expression of heme oxygenase-1 (HO-1), a mediator of cell survival and drug resistance in these cells. The HO-1 inhibitor SMA-ZnPP was subsequently applied and found to sensitize neoplastic mast cells against synthetic triterpenoids and KIT D816V-targeting drugs. Together, application of bardoxolone methyl and omaveloxolone, as single agents or in drug combinations involving HO-1 blockers and/or KIT D816V-targeting drugs, may be a suitable strategy to improve therapy and to overcome resistance in advSM. The clinical value of this combination approach remains to be assessed in clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria.
- Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, 1090 Vienna, Austria.
- Department of Medicine III, Division of Hepatology and Gastroenterology, Medical University of Vienna, 1090 Vienna, Austria.
- Faculty of Pharmaceutical Sciences, Sojo University, Kumamoto 860-0082, Japan.
- Division of Gastroenterology and Hepatology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
- Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, 68167 Mannheim, Germany.
ORCID-Profile: Mathias Schneeweiss-Gleixner, Waliul Islam, Marina Konopleva, Michael Andreeff, Gregor Hoermann, Michel Arock, Klaus Schmetterer, Peter Valent
Förderung
- Medical Scientific Fund of the Mayor of the City of Vienna
- Austrian Science Fund (FWF)
Zitieren
APA
John, M. V., Filik Schüppler, Y., Witzeneder, N., Schneeweiss-Gleixner, M., Peter, B., Berger, D., Stefanzl, G., Ishaq-Parveen, I., Fang, J., Islam, W., Schwaab, J., Reiter, A., Konopleva, M., Andreeff, M., Hoermann, G., Arock, M., Zuber, J., Schmetterer, K., Sperr, W. R., …, & Gleixner, K. V. (2026). Triterpenoid Exposure and HO-1 Blockade Sensitize Neoplastic Mast Cells Against Midostaurin and Avapritinib. Cells. https://doi.org/10.3390/cells15201898
Vancouver
John MV, Filik Schüppler Y, Witzeneder N, Schneeweiss-Gleixner M, Peter B, Berger D, et al. Triterpenoid Exposure and HO-1 Blockade Sensitize Neoplastic Mast Cells Against Midostaurin and Avapritinib. Cells. 2026. doi:10.3390/cells15201898
BibTeX
@article{John2026,
author = {John, Max Vincent and Filik Schüppler, Yüksel and Witzeneder, Nadine and Schneeweiss-Gleixner, Mathias and Peter, Barbara and Berger, Daniela and Stefanzl, Gabriele and Ishaq-Parveen, Isma and Fang, Jun and Islam, Waliul and Schwaab, Juliana and Reiter, Andreas and Konopleva, Marina and Andreeff, Michael and Hoermann, Gregor and Arock, Michel and Zuber, Johannes and Schmetterer, Klaus and Sperr, Wolfgang R and Valent, Peter and Gleixner, Karoline V},
title = {Triterpenoid Exposure and HO-1 Blockade Sensitize Neoplastic Mast Cells Against Midostaurin and Avapritinib},
journal = {Cells},
year = {2026},
doi = {10.3390/cells15201898}
}
EUVIMED